Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pre-screening:~* Signed informed consent for pre-screening~* Male or female participants aged ≥ 18 years~* Participants with histologically confirmed diagnosis of melanoma, glioblastoma/anaplastic astrocytoma, sarcoma or epithelial ovarian cancer/fallopian tube/primary peritoneal cancer~* Availability of archival tumor tissue (5-10 for prescreening, further 20 to be provided at screening)~* ECOG ≤2~Main Screening :~* Positive SLFN12/PDE3A expression in archival tumour~* Minimum life expectancy at least 12 weeks~* Documented radiological disease progression after treatment with all available standard of care therapies for advanced/metastatic disease and at least one measurable lesion~* Adequate bone marrow, liver, and renal function~* Adequate blood clotting~* Left ventricular ejection fraction \>50%~* All AEs due to previous therapies to CTCAE Grade ≤1. Grade ≤2 neuropathy, fatigue, alopecia, or anorexia, for which further resolution is not expected, may be eligible.~* Negative pregnancy test and use of highly effective contraception~* Signed informed consent for main screening~Exclusion Criteria:~Pre-screening:~* Any malabsorption conditions~* Known HIV infection, active HBV or HCV infection~* Known hypersensitivity to PDE3 inhibitors, or excipients in the formulation; concomitant treatment with any other PDE3 inhibitors~* Participants with clinically relevant cardiovascular diseases and/or relevant ECG findings~* Participants with history of hemorrhage, bleeding disorders or platelet function abnormalities, aneurysm or aneurysmal vasculopathy; Participants with arterial thromboembolic events (ATEs) or venous thromboembolic events (VTEs), including transient ischemic attacks or pulmonary embolism within 6 months before the start of BAY 2666605 or deep vein thrombosis within 3 months before the start of BAY 2666605; Participant with a history of gastrointestinal (GI) ulcerations or perforation, fistula formation involving any internal organs.~Main screening~* Moderate or severe hepatic impairment~* History of organ allograft transplantation, including allogeneic bone marrow~* Previous of co-existing cancer(s) distinct in primary site or histology from the cancer evaluated in this study (with few exceptions)~* Participants with any history of primary meningeal tumors and/or Any active symptomatic or untreated central nervous system (CNS) metastases and/or a number of prior and concomitant therapies~* Major surgery, significant trauma, serious non-healing wound, wound healing complications, ulcer or bone fracture within 4wks prior to 1st dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation of BAY2666605 (Type: EXPERIMENTAL): Approximately 7 or 8 dose levels are planned.
- Dose expansion of BAY2666605 (Type: EXPERIMENTAL): Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy